Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1981 Dec;78(12):7670–7673. doi: 10.1073/pnas.78.12.7670

Down syndrome fibroblasts are hyperresponsive to beta-adrenergic stimulation.

J D McSwigan, D R Hanson, A Lubiniecki, L L Heston, J R Sheppard
PMCID: PMC349331  PMID: 6278485

Abstract

The hormonal response to human skin fibroblasts after exposure to beta-adrenergic agonists, prostaglandin E1 (PGE1), and cholera toxin was monitored by intracellular cyclic AMP accumulation. Down syndrome (DS; trisomy 21) cells had an approximately 10-fold greater response to beta-adrenergic agonists than did either normal diploid skin fibroblasts or other aneusomic fibroblast strains (trisomy 13, 18, and 22). The altered response in DS fibroblasts was specific for beta-adrenergic agonists, because treatment of DS or control cells with PGE1 or cholera toxin resulted in the same degree of cyclic AMP accumulation. Experiments with 3-isobutyl-1-methylxanthine, a cyclic nucleotide phosphodiesterase inhibitor, indicated that the increased response of DS fibroblasts was not primarily a function of altered cyclic AMP degradation. Monosomy 21 cells responded less than normal diploid fibroblasts to stimulation by the beta-adrenergic agonist isoproterenol. These findings suggest that genetic information on chromosome 21 participates in regulating the beta-adrenergic response of human fibroblasts.

Full text

PDF
7670

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown B. L., Ekins R. P., Albano J. D. Saturation assay for cyclic AMP using endogenous binding protein. Adv Cyclic Nucleotide Res. 1972;2:25–40. [PubMed] [Google Scholar]
  2. Brown M. S., Goldstein J. L. Receptor-mediated control of cholesterol metabolism. Science. 1976 Jan 16;191(4223):150–154. doi: 10.1126/science.174194. [DOI] [PubMed] [Google Scholar]
  3. Buchwald M. Abnormal levels of 3':5'-cyclic AMP in isoproterenol-stimulated fibroblasts from patients with cystic fibrosis. Proc Natl Acad Sci U S A. 1976 Aug;73(8):2899–2903. doi: 10.1073/pnas.73.8.2899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buchwald M., Mapleson J. L. Adenosine 3':5'-cyclic AMP in fibroblasts from patients with cystic fibrosis and its relationship to secretion. Mod Probl Paediatr. 1976 Oct 24;19:165–174. [PubMed] [Google Scholar]
  5. Drezner M. K., Burch W. M., Jr Altered activity of the nucleotide regulatory site in the parathyroid hormone-sensitive adenylate cyclase from the renal cortex of a patient with pseudohypoparathyroidism. J Clin Invest. 1978 Dec;62(6):1222–1227. doi: 10.1172/JCI109242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Farfel Z., Brickman A. S., Kaslow H. R., Brothers V. M., Bourne H. R. Defect of receptor-cyclase coupling protein in psudohypoparathyroidism. N Engl J Med. 1980 Jul 31;303(5):237–242. doi: 10.1056/NEJM198007313030501. [DOI] [PubMed] [Google Scholar]
  7. Feaster W. W., Kwok L. W., Epstein C. J. Dosage effects for superoxide dismutase-1 in nucleated cells aneuploid for chromosome 21. Am J Hum Genet. 1977 Nov;29(6):563–570. [PMC free article] [PubMed] [Google Scholar]
  8. Franklin T. J., Foster S. J. Leakage of cyclic AMP from human diploid fibroblasts in tissue culture. Nat New Biol. 1973 Nov 28;246(152):119–120. doi: 10.1038/newbio246119a0. [DOI] [PubMed] [Google Scholar]
  9. Gustavson K. H., Wetterberg L., Bäckström M., Ross S. B. Catechol-O-methyltransferase activity in erythrocytes in Down's syndrome. Clin Genet. 1973;4(3):279–280. doi: 10.1111/j.1399-0004.1973.tb01156.x. [DOI] [PubMed] [Google Scholar]
  10. Hagemeijer A., Smit E. M. Partial trisomy 21. Further evidence that trisomy of band 21q22 is essential for Down's phenotype. Hum Genet. 1977 Aug 31;38(1):15–23. doi: 10.1007/BF00295803. [DOI] [PubMed] [Google Scholar]
  11. Harden T. K., Foster S. J., Perkins J. P. Differential expression of components of the adenylate cyclase system during growth of astrocytoma cells in culture. J Biol Chem. 1979 Jun 10;254(11):4416–4422. [PubMed] [Google Scholar]
  12. Harris W. S., Goodman R. M. Hyper-reactivity to atropine in Down's syndrome. N Engl J Med. 1968 Aug 22;279(8):407–410. doi: 10.1056/NEJM196808222790805. [DOI] [PubMed] [Google Scholar]
  13. Hösli P., Vogt E. High alkaline phosphatase activity in isoproterenol stimulated fibroblast cultures from patients with numerically unbalanced chromosomal aberrations. Clin Genet. 1979 Jun;15(6):487–494. doi: 10.1111/j.1399-0004.1979.tb00830.x. [DOI] [PubMed] [Google Scholar]
  14. KRIVIT W., GOOD R. A. Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J Dis Child. 1957 Sep;94(3):289–293. doi: 10.1001/archpedi.1957.04030040075012. [DOI] [PubMed] [Google Scholar]
  15. Kelly L. A., Butcher R. W. The effects of epinephrine and prostaglandin E-1 on cyclic adenosine 3':5'-monophosphate levels in WI-38 fibroblasts. J Biol Chem. 1974 May 25;249(10):3098–3102. [PubMed] [Google Scholar]
  16. LEJEUNE J., GAUTIER M., TURPIN R. Etude des chromosomes somatiques de neuf enfants mongoliens. C R Hebd Seances Acad Sci. 1959 Mar 16;248(11):1721–1722. [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Lake C. R., Ziegler M. G., Coleman M., Kopin I. J. Evaluation of the sympathetic nervous system in trisomy-21 (Down's syndrome). J Psychiatr Res. 1979;15(1):1–6. doi: 10.1016/0022-3956(79)90002-5. [DOI] [PubMed] [Google Scholar]
  19. Naeim F., Walford R. L. Disturbance of redistribution of surface membrane receptors on peripheral mononuclear cells of patients with Down's syndrome and of aged individuals. J Gerontol. 1980 Sep;35(5):650–655. doi: 10.1093/geronj/35.5.650. [DOI] [PubMed] [Google Scholar]
  20. Paton G. R., Silver M. F., Allison A. C. Comparison of cell cycle time in normal and trisomic cells. Humangenetik. 1974;23(3):173–182. doi: 10.1007/BF00285103. [DOI] [PubMed] [Google Scholar]
  21. Rapaport F. T., Bach F. H. Genetic studies of cell-surface determinants in human developmental anomalies--a preliminary report. Transplant Proc. 1973 Jun;5(2):1139–1143. [PubMed] [Google Scholar]
  22. Roth J., Lesniak M. A., Bar R. S., Muggeo M., Megyesi K., Harrison L. C., Flier J. S., Wachslicht-Rodbard H., Gorden P. An introduction to receptors and receptor disorders. Proc Soc Exp Biol Med. 1979 Oct;162(1):3–12. doi: 10.3181/00379727-162-40608. [DOI] [PubMed] [Google Scholar]
  23. Schneider E. L., Epstein C. J. Replication rate and lifespan of cultured fibroblasts in Down's syndrome. Proc Soc Exp Biol Med. 1972 Dec;141(3):1092–1094. doi: 10.3181/00379727-141-36940. [DOI] [PubMed] [Google Scholar]
  24. Segal D. J., McCoy E. E. Studies on Down's syndrome in tissue culture. I. Growth rates and protein contents of fibroblast cultures. J Cell Physiol. 1974 Feb;83(1):85–90. doi: 10.1002/jcp.1040830112. [DOI] [PubMed] [Google Scholar]
  25. Shapiro B. L. Amplified developmental instability in Down's syndrome. Ann Hum Genet. 1975 May;38(4):429–437. doi: 10.1111/j.1469-1809.1975.tb00632.x. [DOI] [PubMed] [Google Scholar]
  26. Sinet P. M., Lejeune J., Jerome H. Trisomy 21 (Down's syndrome). Glutathione peroxidase, hexose monophoshate shunt and I.Q. Life Sci. 1979 Jan 1;24(1):29–33. doi: 10.1016/0024-3205(79)90276-5. [DOI] [PubMed] [Google Scholar]
  27. Slate D. L., Ruddle F. H. Genetics of the interferon system. Pharmacol Ther. 1979;4(1):221–230. doi: 10.1016/0163-7258(79)90020-2. [DOI] [PubMed] [Google Scholar]
  28. Tan Y. H., Schneider E. L., Tischfield J., Epstein C. J., Ruddle F. H. Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state. Science. 1974 Oct 4;186(4158):61–63. doi: 10.1126/science.186.4158.61. [DOI] [PubMed] [Google Scholar]
  29. Tan Y. H., Tischfield J., Ruddle F. H. The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21. J Exp Med. 1973 Feb 1;137(2):317–330. doi: 10.1084/jem.137.2.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wisniewski K., Cobill J. M., Wilcox C. B., Caspary E. A., Williams D. G., Wisniewski H. M. T lymphocytes in patients with Down's syndrome. Biol Psychiatry. 1979 Jun;14(3):463–471. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES